We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02 (Co-SOFT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00659373
Recruitment Status : Completed
First Posted : April 16, 2008
Results First Posted : July 25, 2016
Last Update Posted : July 25, 2016
Sponsor:
Collaborators:
Information provided by (Responsible Party):

Study Description
Brief Summary:

RATIONALE: Learning about the long-term effects of adjuvant tamoxifen (T), adjuvant tamoxifen with ovarian function suppression (T+OFS), and exemestane with ovarian function suppression (E+ OFS) on brain function may help doctors plan cancer treatment.

PURPOSE: This study is looking at brain function in premenopausal women who are receiving adjuvant tamoxifen (T) alone against those receive adjuvant tamoxifen (T+OFS) or exemestane (E+OFS) with ovarian function suppression (OFS) for early-stage breast cancer on clinical trial IBCSG-2402.


Condition or disease Intervention/treatment Phase
Breast Cancer Fatigue Sleep Disorders Drug: Tamoxifen Drug: triptorelin Drug: Exemestane Phase 3

Detailed Description:

OBJECTIVES:

Primary:

* To evaluate and compare the changes in cognitive function over one year in premenopausal breast cancer patients who receive adjuvant tamoxifen (T) alone against those receive adjuvant tamoxifen (T+OFS) or exemestane (E+OFS) with ovarian function suppression (OFS).

OUTLINE: This is a multicenter study.

Objective cognitive function was measured with the CogState computerized test battery. The CogState battery consists of seven tasks: Detection, Identification, Monitoring, Memory, Learning, International Shopping List Task (ISLT), and ISLT-Delayed Recall. Performance speed is measured for the Detection, Identification and Monitoring tasks and performance accuracy is measured for the Memory, Learning, ISLT, and ISLT-Delayed Recall. Measures of performance speed are normalized using measures of performance accuracy (%) are normalized using arcsine transformation. The main outcome measure is a composite score which is the average of these task scores (after transformation and standardization by age-specific norms). Patients complete these assessments at baseline (i.e. before start of protocol hormonal therapy) and approximately one year after randomization to the parent IBCSG 24-02 (SOFT) study.

Data were collected separately for the T+OFS and E+OFS participants in the parent study, IBCSG 24-02 (SOFT). The sample size for this Co-SOFT substudy was small, so the analysis plan was revised to pre-specify collective analysis for all patients receiving OFS.


Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 86 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Official Title: Investigating Cognitive Function for Patients Participating in the SOFT Trial in Selected Centers
Study Start Date : December 2007
Primary Completion Date : December 2014
Study Completion Date : April 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Active Comparator: Tamoxifen
Tamoxifen 20mg orally daily for 5 years
Drug: Tamoxifen
Other Name: Nolvadex
Experimental: T+OFS
Tamoxifen 20mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation)
Drug: Tamoxifen
Other Name: Nolvadex
Drug: triptorelin
Other Names:
  • GnRH analogue
  • Trelstar Depot
  • Decapeptyl Depot
Experimental: E+OFS
Exemestane 25mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation)
Drug: triptorelin
Other Names:
  • GnRH analogue
  • Trelstar Depot
  • Decapeptyl Depot
Drug: Exemestane
Other Name: Aromasin


Outcome Measures

Primary Outcome Measures :
  1. Change in Cognitive Function Over 1 Year in Premenopausal Breast Cancer Patients Who Receive Adjuvant Tamoxifen (T) Alone Against Those Receive Adjuvant Tamoxifen (T+OFS) or Exemestane (E+OFS) With Ovarian Function Suppression (OFS) [ Time Frame: 1 year after patient randomization to parent IBCSG 24-02 study ]
    Objective cognitive function measured with CogState, a computerized test battery of 7 tasks: Detection, Identification, Monitoring, Memory, Learning, International Shopping List Task (ISLT) and ISLT-Delayed Recall. Performance speed is measured for Detection/Identification/Monitoring and performance accuracy is measured for Memory/Learning/ISLT/ISLT-Delayed Recall. Performance speed calculated as mean of the log10 transformed reaction time for correct responses (lower score=better); performance accuracy calculated as arcsine transformation of the proportion of correct responses (higher scores=better). Main outcome measure is a composite score (average of task scores after transformation and standardization by age-specific norms). A positive standardized score indicates that a patient performed better than average; a negative standardized score indicates below average results. Patients complete assessments at baseline and 1 year after randomization to parent IBCSG 24-02 (SOFT) study.


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 120 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically confirmed breast cancer

    • Completely resected disease
  • Registered for clinical trial IBCSG-2402, but not yet started protocol hormonal therapy

    • Has not yet received any of the following adjuvant endocrine therapy, either before or after registration on IBCSG-2402:

      • Tamoxifen, exemestane, or gonadotropin-releasing hormone (GnRH) agonist
      • Ovarian irradiation
      • Bilateral oophorectomy
  • Hormone receptor status:

    • Estrogen and/or progesterone receptor positive

      • Each tumor must be hormone receptor positive

PATIENT CHARACTERISTICS:

  • Premenopausal
  • Can speak and read the local language(s) fluently

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00659373


Locations
United States, California
Mercy General Hospital
Sacramento, California, United States, 95819
United States, Colorado
Front Range Cancer Specialists
Fort Collins, Colorado, United States, 80528
United States, Connecticut
Norwalk Hospital
Norwalk, Connecticut, United States, 06856
United States, Georgia
Piedmont Hospital
Atlanta, Georgia, United States, 30309
Northside Hospital Cancer Center
Atlanta, Georgia, United States, 30342-1611
Saint Joseph's Hospital of Atlanta
Atlanta, Georgia, United States, 30342-1701
CCOP - Atlanta Regional
Atlanta, Georgia, United States, 30342
United States, Indiana
CCOP - Northern Indiana CR Consortium
South Bend, Indiana, United States, 46601
United States, New Hampshire
New Hampshire Oncology - Hematology, PA at Payson Center for Cancer Care
Concord, New Hampshire, United States, 03301
United States, New York
Don Monti Comprehensive Cancer Center at North Shore University Hospital
Manhasset, New York, United States, 11030
United States, North Carolina
Mission Hospitals - Memorial Campus
Asheville, North Carolina, United States, 28801
Batte Cancer Center at Northeast Medical Center
Concord, North Carolina, United States, 28025
United States, Pennsylvania
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104-4283
Canada, British Columbia
British Columbia Cancer Agency - Centre for the Southern Interior
Kelowna, British Columbia, Canada, V1Y 5L3
Canada, Ontario
Ottawa Hospital Regional Cancer Centre - General Campus
Ottawa, Ontario, Canada, K1H 1C4
Sponsors and Collaborators
International Breast Cancer Study Group
National Cancer Institute (NCI)
Breast Cancer Trials, Australia and New Zealand
Cancer and Leukemia Group B
Investigators
Study Chair: Juerg Bernhard, PhD International Breast Cancer Study Group
Study Chair: Kelly-Anne Phillips Peter MacCallum Cancer Centre, Australia
Study Chair: Timothy Ahles, MD Cancer and Leukemia Group B
More Information

Publications:
Responsible Party: International Breast Cancer Study Group
ClinicalTrials.gov Identifier: NCT00659373     History of Changes
Other Study ID Numbers: CDR0000594003
IBCSG-24-02-ANZ0701
ANZ0701
CALGB-IBCSG-24-02-ANZ0701
First Posted: April 16, 2008    Key Record Dates
Results First Posted: July 25, 2016
Last Update Posted: July 25, 2016
Last Verified: July 2016

Keywords provided by International Breast Cancer Study Group:
cognitive/functional effects
psychosocial effects of cancer and its treatment
fatigue
sleep disorders
stage IA breast cancer
stage IB breast cancer
stage II breast cancer
stage IIIA breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Fatigue
Sleep Wake Disorders
Parasomnias
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Signs and Symptoms
Nervous System Diseases
Neurologic Manifestations
Mental Disorders
Tamoxifen
Exemestane
Triptorelin Pamoate
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Selective Estrogen Receptor Modulators
Estrogen Receptor Modulators
Bone Density Conservation Agents
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Luteolytic Agents
Contraceptive Agents, Female